<i>Notes from the Field</i>: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus — Five States, October 2023–February 2024
Crystal M. Gigante, Jade Takakuwa, D McGrath, C. Kling, Todd G. Smith, Mengfei Peng, Kimberly Wilkins, Jacob M. Garrigues, Holly Taylor, Hannah J. Barbian, Alyse Kittner, Danielle Haydel, Emma Ortega, Gillian Richardson, Julie Hand, Jill K. Hacker, Alex Espinosa, Monica Haw, Chantha Kath, Meilan Bielby, Kirstin Short, Kimberly S. Johnson, Nelson De La Cruz, Whitni Davidson, Christine Hughes, Nicole Green, Nicolle Baird, Agam K. Rao, Christina L. Hutson
Abstract
(1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.